Wednesday, March 22, 2017
Company News: Page (1) of 1 - 02/17/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Thyrve Microbiome Raises Seed Round From PivotNorth and Plug & Play Ventures to Improve Wellness Through Your Stomach
Nation's first monthly testing subscription model providing detailed, personalized overview of gut flora paired with potent probiotic products aims to improve health and support research.
(February 17, 2017)

SAN FRANCISCO, Feb. 17, 2017 /PRNewswire/ -- Thryve, providers of high quality microbiotics and microbiome testing, today announced it has closed a seed round of financing from PivotNorth Ventures and Plug & Play Ventures. Thryve recently launched the first at home microbiome testing kit and probiotics subscription service on the market to wide appeal. 

Thryve's powerful monthly Gut Wellness Score provides consumers key insight into their health. The score analyzes the state of gut bacteria in the body, which clinical research has shown impacts not only overall all health, but also play a role the treatment and prevention of chronic diseases including obesity, cystic fibrosis, and Alzheimer's. With each monthly box, subscribers also receive high quality probiotics aimed to improve gut health and overall wellness.

"At Plug & Play we believe that Thryve has a unique method to bringing a very common bacteria-based industry practice to your own home," said Alireza Masrour, Managing Partner at Plug & Play Ventures. "They are providing a platform to gather microbiome data, provide actionable insights, and offer a complete understanding of customer health needs on a regular basis via a completely organic approach."

Subscriptions start from $59.95 per month.

The Thryve Microbiome Testing Kit is available now at

Bettering Health, Improving Science

Thryve's unique testing kit requires only a small stool sample taken in the privacy of the user's own home and is engineered to provide the most accurate results, with all samples are tested at Thryve's partner laboratory at the world-renowned University of Chicago Argonne National Laboratory.

Thryve helps users make better decisions about their health based on easy to understand data and personalized diet and lifestyle recommendations, along with monthly supplies of its high potency probiotics. Subscribers receive reports and recommendations backed by over 3,000 microbiome studies and up to date research. Thryve users can also opt to provide anonymized data from their own microbiome tests which will help increase the available data to scientists and help expand knowledge in the growing field of microbiome and probiotic research.

"We wanted to create a company that not only provided a valuable service to our customers, but also make a genuinely lasting impact in health sciences by crowdsourcing data that will prove invaluable to studies in the microbiome space," said Richard Lin, CEO of Thryve. "We are gratified that our investment partners share are vision, and look forward to working with them to expand Thryve's unique products and services."

About Thryve

Thryve is the only monthly subscription service that combines customized testing of the microbiome with a personalized probiotic created specifically for the individual. Thryve's platform connects individuals with leading scientific research and robust online community to come together and uncover meaningful and actionable insights into tackling microbiome related diseases. For more information, visit

Media Contact: Lisa Wang,, 1-888-317-4687 ext. 703

To view the original version on PR Newswire, visit:


Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:Diet, Surgery, Lifestyle, Science,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • David A. Halsey MD, named first vice president of the American Academy of Orthopaedic Surgeons
  • Cryotherapy and Cryosurgery Market Rises High Incidence Of Cancer - IndustryARC
  • Global Radiology Oncology Surgical Robot Device Markets at $4 billion in 2015 are anticipated to reach $7.3 billion by 2022 - Acute Market Reports
  • FDA Approves Xadago® (Safinamide) for Parkinsons Disease (PD) Patients
  • Genomics Market Being Viewed As The Key To Achieving Human Immortality - IndustryARC Research

  • MOLOGEN AG: New strategic orientation, successful capital measures and notable study progress in 2016
  • FREEMAXDESK Brings In BEST Power Adjustable Desk Converter At Rates To Fit Pockets
  • Global Automotive Ceramics Market Size, Share, Growth Rate and Forecast by 2022 - Market Research Report 2017
  • Marcus Theatres® To Host Inaugural CineLatino Milwaukee Film Festival At South Shore Cinema, April 27-30
  • FACIT Announces Investment in Propellon Therapeutics

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines